Clinical Trial: NCT04732598
A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Japanese Foundation for Cancer Research |
| Information Provided By: | Japanese Foundation for Cancer Research |
| Last Update Posted: | 2026-04-21 |
Study Overview
Brief Summary
JCOG1919E (AMBITION) is a randomized, open-label, phase 3 trial to evaluate efficacy and safety of bevacizumab and paclitaxel in combination with atezolizumab comparing to bevacizumab and paclitaxel in patients with HR-positive HER2 negative metastatic breast cancer.
Official Title
A Phase III, Randomized Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Paclitaxel + bevacizumab therapy
- Drug: Paclitaxel + bevacizumab + atezolizumab
Other Study ID Numbers
- JCOG1919E
Start Date (Actual)
2021-01-21
Primary Completion Date (Actual)
2025-09-12
Study Completion Date (Actual)
2026-03-13
Enrollment (Actual)
281
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Japanese Foundation for Cancer Research |
| Information Provided By: | Japanese Foundation for Cancer Research |
| Last Update Posted: | 2026-04-21 |
Study Overview
Brief Summary
JCOG1919E (AMBITION) is a randomized, open-label, phase 3 trial to evaluate efficacy and safety of bevacizumab and paclitaxel in combination with atezolizumab comparing to bevacizumab and paclitaxel in patients with HR-positive HER2 negative metastatic breast cancer.
Official Title
A Phase III, Randomized Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Paclitaxel + bevacizumab therapy
- Drug: Paclitaxel + bevacizumab + atezolizumab
Other Study ID Numbers
- JCOG1919E
Start Date (Actual)
2021-01-21
Primary Completion Date (Actual)
2025-09-12
Study Completion Date (Actual)
2026-03-13
Enrollment (Actual)
281
Study Type
Interventional
Phase
Phase 3